Psilocybin, a psychedelic compound being tested as a treatment for mental health conditions, strongly activates serotonin receptors found not only in the brain but also in the gastrointestinal tract. Despite evidence that gut-brain signaling is disrupted in conditions where psilocybin is used, no research has examined whether its effects on the gut contribute to mental health improvements. This opinion piece argues that psilocybin's peripheral actions in the gut may play a role in its rapid and lasting therapeutic effects, and that understanding all sites of action could guide more targeted drug development.
Psilocybin, a serotonergic psychedelic, shows promise for treating anorexia nervosa by enhancing cognitive flexibility and modifying reward processing—two core processes disrupted in the disorder. Its effects are primarily mediated by the 5-HT2A receptor, but recent evidence indicates broader interactions with dopaminergic pathways in brain regions like the prefrontal cortex and nucleus accumbens. Rodent models demonstrate that psilocybin induces rapid and enduring neuroplastic changes, improving cognitive flexibility through complex neurochemical mechanisms. Advances in real-time neurochemical recording now allow simultaneous monitoring of serotonin and dopamine signaling, which will provide insights into their coordinated actions during cognitive performance. Further research into psilocybin's dual modulation of these systems is needed to optimize therapeutic applications for anorexia nervosa.